Belgian anti-trust regulators are probing Roche over concerns that the drug company took steps to delay the entry of biosimilar versions of two of its cancer medicines. In a brief statement ...

We explore the history of global pharmaceutical group Hoffmann-La Roche from where it first began, to its core structure and its focus for the future in personalised medicine. Roche was found in ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369] Draft guidance Technology appraisal guidance 2 April ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

European shares bounced back on Wednesday following four sessions of declines on optimism around positive developments in the Ukraine-Russia conflict, while a cooler-than-expected U.S. inflation ...

After hours: March 19 at 4:05:10 PM EDT Loading Chart for MDCX ...